Back to search results

Phase 1 Study of SPY002-072 in Healthy Volunteers

This study is testing an experimental drug called SPY002-072 in healthy volunteers. It's a Phase 1 study, which means it's one of the first times this drug is being given to people. Researchers want to see if SPY002-072 is safe and how your body handles it. Some participants will receive SPY002-072, while others will receive a placebo (an inactive substance like a sugar pill). The main goal is to track any side effects over about 40 weeks. You can join if you are a healthy man or woman between 18 and 60 years old and can attend all study visits. The study plans to enroll 56 people, but its current recruitment status is unclear.

Study design
This is a Phase 1, randomized, double-blind (meaning neither you nor your doctor will know if you're getting the study drug or placebo), placebo-controlled study involving 56 healthy participants.
What's involved
You would need to attend necessary visits to the study center, stay at the site for a period, and return for outpatient visits.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for treatment-related side effects for up to 40 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06622070

A Study of SPY002-072 in Healthy Volunteers

Completed
PHASE1Ages 18–60InterventionalBasic science
Spyre Therapeutics, Inc.
~40 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:SPY002-072Placebo

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Treatment emergent adverse events
Measured over Up to 40 weeks

Conditions

Healthy

Explore related trials

Healthy

Where it's being run

2 sites across 2 states
California1
Quebec1

Study leadership

  • Joshua Friedman, MD · STUDY_CHAIR · Spyre Therapeutics

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Healthy men and women
Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits

Exclusion

Participation in more than one cohort
Evidence of clinically significant abnormality or disease
Known history of illicit drug use or drug abuse, cannabis/cannabinoid use, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent
History of severe allergic reactions or hypersensitivity
Donation or loss of ≥ 1 unit of whole blood within 1 month prior to dosing

What this trial measures

  • Treatment emergent adverse eventsUp to 40 weeks

    Incidence, severity, and causal relationship of TEAEs